HOME >> BIOLOGY >> NEWS
Gene silencing directs muscle-derived stem cells to become bone-forming cells

BALTIMORE - Using a relatively new technology called RNA interference to turn off genes that regulate cell differentiation, University of Pittsburgh researchers have demonstrated they can increase the propensity of muscle-derived stem cells (MDSCs) to become bone-forming cells. Based on these results, the investigators believe that by turning off specific genetic factors they can control the capacity of MDSCs as a means of treating various musculoskeletal diseases and injuries.

RNA interference is a simple yet powerful technique that uses short interfering RNAs (siRNAs) small molecules that prevent a gene from being expressed to turn off the production of specific proteins in a cell. In their study, the Pitt researchers generated siRNAs to two mouse genes: MyoD1, a master gene that regulates the formation of muscle cells or fibers (myogenesis), and Smad6, which encodes a molecule that specifically inhibits a cell's ability to respond to bone-forming, or osteogenic, signals.

When the researchers examined cultured cells in which myogenesis was inhibited, they found a significant increase in the cells' bone-forming potential. However, contrary to their expectations, the researchers did not observe any bone formation when the cells were implanted in skeletal muscle. Yet, when they turned off ostegenic inhibition in these same cells using Smad6 siRNA prior to implanting them in mice, 60 percent of the mice developed radiologically detectable bone within three weeks.

"By understanding the genetic mechanisms that regulate a cell's propensity to differentiate into one type of cell line over another, we may be able to regulate their ability to generate bone for the treatment of various diseases and injuries of the musculoskeletal system, such as osteoporosis or severe fractures," said first author Jonathan B. Pollett, Ph.D., research associate, department of orthopaedic surgery, Children's Hospital of Pittsburgh. Corresponding author Johnny Huard,
'"/>


1-Jun-2006


Page: 1 2

Related biology news :

1. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
2. Newly identified mechanism for silencing genes points to possible anti-cancer strategies
3. Pathway toward gene silencing described in plants
4. miRNA-mediated silencing of mRNAs
5. New mechanism for essential genome-wide gene silencing identified
6. Proteins role in hemoglobin gene silencing identified
7. Prediction of a prokaryotic RNA-silencing system
8. Twin molecular scissors link creation of microRNAs with gene-silencing
9. Gene silencing technique offers new strategy for treating, curing disease
10. Molecular steps involved in the creation of gene-silencing microRNAs identified
11. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma

Post Your Comments:
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... Conn. , Jan. 26, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... new corporate website ( http://www.nxt-id.com/ ) as part of ... smart wallet. The Company launched its new consumer website ... Gino Pereira , CEO of NXT-ID said, "Our new ...
(Date:2/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/6lngtl/global_biometrics ... "Global Biometrics Market (2014-2020): Market Forecast By Technologies, ... to their offering. , In ... is anticipated to overtake North America ... spending towards IT security, government biometric based projects ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
(Date:3/4/2015)... 4, 2015  BioClinica®, Inc., a leading ... today announced that clinical trial professionals representing ... its annual European User Conference in ... the use of its eClinical technologies to ... include: the Microsoft Office-Smart OnPoint CTMS; Express ...
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
(Date:3/3/2015)... TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. ... therapeutics and molecular diagnostics that target the underlying mechanisms ... and seventh-month period ended December 31, 2014. ... year end from May 31 to December 31. As ... reporting today are for the quarter and the seven ...
(Date:3/3/2015)... 03, 2015 Experts and industry insiders ... one event: the Alltech REBELation exploring innovation, inspiration and ... Now in its 31st year, Alltech’s annual international conference ... and the opportunity to join the REBELation at an ... 11:59 p.m. EST, at which point the standard early ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
Cached News: